The Personalized Medicine Coalition 2015 Annual Report summarizes the organization's work in education, advocacy, and impact over the past year. It highlights key events including a Congressional briefing on personalized medicine that educated over 125 people, including 50 Congressional staffers. The report also outlines challenges to personalized medicine such as obstacles in science, regulation, and reimbursement, but notes the biopharmaceutical industry remains committed with over 40% of drugs in development being personalized medicines.
Quality and Cost of Accreditation's In Healthcare by Mahboob ali khan ,MHA,CPHQ Healthcare consultant
Accreditations and quality assurance systems have also been observed to reduce the average cost of hospitalization. This clearly indicates that accreditations and quality assurance systems help hospitals to streamline their functions and processes, minimize wastage and thereby aid in enhancing quality and reducing cost of care.
Has Accreditation made a difference in Healthcare Delivery in India by Dr.Mah...Healthcare consultant
There is consistent evidence that shows that accreditation programs improve the process of care provided by healthcare services. There is considerable evidence to show that accreditation programs improve clinical outcomes of a wide spectrum of clinical conditions. Accreditation programs should be supported as a tool to improve the quality of healthcare services.
This document discusses churning (involuntary movement between health insurance programs) under the Affordable Care Act. It aims to identify the characteristics of individuals likely to churn between Medicaid and Qualified Health Plans (QHPs), and the health plans best able to serve churning populations. The document introduces different types of health plans and examines their presence in several states' insurance exchanges. It outlines how churning will occur under the ACA and analyzes the experiences of Hawaii, New York, and Maryland to identify policies that can reduce churning, such as market alignment of insurers and strong data tools. The key findings are that market alignment dramatically reduces churning problems, data-driven health plans can help states address churning
The document presents a strategic framework for the U.S. Department of Health and Human Services (HHS) to improve health outcomes for individuals with multiple chronic conditions. Approximately 75 million Americans have two or more chronic illnesses like arthritis, diabetes, and heart disease. These individuals face higher costs, worse health outcomes, and complex care needs. The framework aims to shift care from focusing on single diseases in isolation to a holistic approach that addresses all of a person's conditions. It establishes goals, objectives, and strategies for HHS agencies to better coordinate care, research, and policies related to multiple chronic conditions.
The document discusses health literacy as it relates to medication and the use and delivery of healthcare. It analyzes reports from the National Academies of Sciences on these topics. For medication, it describes progress made in standardizing drug labels but notes more is needed. It also discusses using technology like apps and electronic records to promote health literacy. For healthcare delivery, it highlights the importance of health literacy in reducing complexity and disparities. While policies have helped, stronger communication skills are still required. The document proposes a case study on screening for low health literacy using the Newest Vital Sign assessment tool to test hypotheses about time and cost constraints.
This document discusses the need to harmonize the process for reporting potential conflicts of interest in health care and life sciences. It notes that individuals are currently required to provide this information to various organizations in non-identical, time-consuming ways. The document proposes creating a common set of disclosure elements and a standardized digital format that individuals can use to easily report relationships to multiple requesting organizations. This would reduce burden on individuals and allow organizations to access standardized data more efficiently. It outlines goals and approaches discussed by working groups to define common elements and a process for centralized storage and retrieval of disclosure information.
National Health Policy Introduction, NHP 1983, NHP 2000, NHP 2002, NHP 2017, Seven Priority areas, Sustainable Developmental (SDGs), Public and Private health system in India, National Health Mission (NHM),Sustainable Development Goals (SDGs), International Pharmaceutical Federation Development Goal (FIP),
Surgeons are major contributors to the opioid epidemic as they commonly prescribe opioids in the perioperative period. There are no guidelines for outpatient opioid prescribing by surgeons. The Michigan Opioid Prescription Engagement Network aims to address this issue through education of surgeons, measurement of prescribing practices, driving improvement, and community engagement. The goal is to minimize excess opioid prescribing while maintaining adequate pain management, especially for those at high risk of prolonged use.
Quality and Cost of Accreditation's In Healthcare by Mahboob ali khan ,MHA,CPHQ Healthcare consultant
Accreditations and quality assurance systems have also been observed to reduce the average cost of hospitalization. This clearly indicates that accreditations and quality assurance systems help hospitals to streamline their functions and processes, minimize wastage and thereby aid in enhancing quality and reducing cost of care.
Has Accreditation made a difference in Healthcare Delivery in India by Dr.Mah...Healthcare consultant
There is consistent evidence that shows that accreditation programs improve the process of care provided by healthcare services. There is considerable evidence to show that accreditation programs improve clinical outcomes of a wide spectrum of clinical conditions. Accreditation programs should be supported as a tool to improve the quality of healthcare services.
This document discusses churning (involuntary movement between health insurance programs) under the Affordable Care Act. It aims to identify the characteristics of individuals likely to churn between Medicaid and Qualified Health Plans (QHPs), and the health plans best able to serve churning populations. The document introduces different types of health plans and examines their presence in several states' insurance exchanges. It outlines how churning will occur under the ACA and analyzes the experiences of Hawaii, New York, and Maryland to identify policies that can reduce churning, such as market alignment of insurers and strong data tools. The key findings are that market alignment dramatically reduces churning problems, data-driven health plans can help states address churning
The document presents a strategic framework for the U.S. Department of Health and Human Services (HHS) to improve health outcomes for individuals with multiple chronic conditions. Approximately 75 million Americans have two or more chronic illnesses like arthritis, diabetes, and heart disease. These individuals face higher costs, worse health outcomes, and complex care needs. The framework aims to shift care from focusing on single diseases in isolation to a holistic approach that addresses all of a person's conditions. It establishes goals, objectives, and strategies for HHS agencies to better coordinate care, research, and policies related to multiple chronic conditions.
The document discusses health literacy as it relates to medication and the use and delivery of healthcare. It analyzes reports from the National Academies of Sciences on these topics. For medication, it describes progress made in standardizing drug labels but notes more is needed. It also discusses using technology like apps and electronic records to promote health literacy. For healthcare delivery, it highlights the importance of health literacy in reducing complexity and disparities. While policies have helped, stronger communication skills are still required. The document proposes a case study on screening for low health literacy using the Newest Vital Sign assessment tool to test hypotheses about time and cost constraints.
This document discusses the need to harmonize the process for reporting potential conflicts of interest in health care and life sciences. It notes that individuals are currently required to provide this information to various organizations in non-identical, time-consuming ways. The document proposes creating a common set of disclosure elements and a standardized digital format that individuals can use to easily report relationships to multiple requesting organizations. This would reduce burden on individuals and allow organizations to access standardized data more efficiently. It outlines goals and approaches discussed by working groups to define common elements and a process for centralized storage and retrieval of disclosure information.
National Health Policy Introduction, NHP 1983, NHP 2000, NHP 2002, NHP 2017, Seven Priority areas, Sustainable Developmental (SDGs), Public and Private health system in India, National Health Mission (NHM),Sustainable Development Goals (SDGs), International Pharmaceutical Federation Development Goal (FIP),
Surgeons are major contributors to the opioid epidemic as they commonly prescribe opioids in the perioperative period. There are no guidelines for outpatient opioid prescribing by surgeons. The Michigan Opioid Prescription Engagement Network aims to address this issue through education of surgeons, measurement of prescribing practices, driving improvement, and community engagement. The goal is to minimize excess opioid prescribing while maintaining adequate pain management, especially for those at high risk of prolonged use.
The study aimed to investigate associations between regulatory policy, workforce capacity, and health outcomes using Medicaid data from four states. However, the analysis found significant data quality issues. Key variables like service provider specialty were missing or incomplete, preventing valid conclusions about the proportion of services provided by nurse practitioners and physician assistants. At best, Alabama had 85% reporting but showed nurse practitioners and physician assistants providing significantly fewer services than medical doctors for selected chronic conditions despite making up over half of primary care workforce capacity. Overall, the Medicaid data proved inadequate for the research purposes due to inconsistent and missing coding across states.
This study assessed health care costs and utilization among union members from 2008-2010, comparing those who received primary care from providers participating in a public health initiative (PCIP) versus non-participating providers. Members accessing PCIP providers saw a 16% decrease in hospitalizations for chronic conditions, whereas non-PCIP members saw a 15% increase. PCIP access was associated with lower inpatient utilization and costs. Specialty care increased more for PCIP members with diabetes and hypertension. Overall, the results suggest population health initiatives incorporating electronic health records can reduce health care costs by decreasing hospitalizations for better chronic disease management.
Muir Gray at the First National Conference on Health Care Quality RegistersTHL
The document discusses increasing value in healthcare systems through a "Triple Value Healthcare" approach. It proposes focusing on personal value for individuals, population value for given populations, and technical value through optimizing outcomes and resource use. Key strategies include providing full information to patients, shifting resources from overused to underused areas, developing population-based systems and networks, and creating a culture of stewardship. The goal is to improve outcomes while making the best use of limited resources.
This document discusses the role of pharmacists in public health. It begins by outlining objectives related to identifying pharmacists' functions in public health, explaining their relevance and involvement, and listing health challenges. It then provides historical context of pharmacists' education in public health from 1932-2010. The document poses four questions to consider pharmacists' roles, including whether there is an unmet public health need pharmacists could fill. It argues pharmacists have skills to address issues like medication safety and management. Statistics on medication use and issues in the US demonstrate an unmet need pharmacists are well-suited to address.
The Precision Medicine Initiative is a $215 million effort to revolutionize disease treatment through personalized care. It will create a voluntary national research cohort of over 1 million Americans to share health data to accelerate discoveries. The goals are to develop more effective cancer treatments through genetic testing and clinical trials, create an open research platform for the cohort to partner on studies, and ensure strong privacy protections for health information. The initiative aims to translate precision medicine successes into broader application through public-private partnerships and regulatory modernization.
The goal of this webinar was to help healthcare professionals improve care coordination for patients with advanced illness and to reduce hospital readmissions and length of stay.
The goal of this webinar is to help hospice and healthcare professionals understand the history, philosophy and practice of hospice care and palliative care, including common myths and misconceptions, common diagnoses for hospice referrals, identification of hospice-eligible patients, reimbursement for hospice services, and the benefits of advance care planning and early referrals.
The document discusses Quality Use of Medicines (QUM), which aims to ensure optimal health outcomes from medication use. QUM focuses on selecting management options wisely, choosing suitable medicines appropriately, and using medicines safely and effectively. The National Medicines Policy also aims to ensure timely access to medicines, quality products, quality use, and a viable medicines industry. Key partners in achieving QUM include healthcare providers and recipients, as well as governments, industry, and educators.
Reducing Readmissions and Length of Stay | VITAS HealthcareVITAS Healthcare
Hospice can help reduce hospital readmissions and lengths of stay for patients with serious illnesses like heart failure. By providing comprehensive care, including nursing support 24 hours a day, palliative care physician support, medications, equipment, and targeted programs for conditions like CHF, hospice can help meet patient goals of comfort and avoiding inappropriate hospitalizations. For the patient with heart failure described in the case study, hospice could help prevent readmissions and allow the patient to focus on quality of life rather than further medical interventions by providing end-of-life care in their home.
The demand for healthcare services is driven by both consumption and investment motives. As consumption goods, healthcare makes people feel better, and as investment goods, better health increases productivity. Patients rely on healthcare professionals to evaluate their needs and make decisions. Demand is influenced by income, price, education, marital status, age, gender, access to facilities, household size, and insurance coverage. Higher incomes, education, prices, and insurance increase demand, while single and older individuals also tend to use more services.
This document discusses pharmacology in the sexual health setting. It focuses on developing knowledge to safely administer prescribed and nurse-initiated medications commonly used to treat STIs. Key points include understanding STI natural histories, assessing clients for medication administration, and ensuring quality use of medicines by selecting options wisely, choosing suitable medications, and using medications safely and effectively. Nurses must be familiar with medication actions, contraindications, and guidelines for administration.
The document discusses quality cancer care and outlines several principles and recommendations. It presents 12 principles for quality cancer care established by the National Coalition for Cancer Survivorship, including the rights of cancer patients and survivors to access affordable care, clinical trials, psychosocial services and follow up care. It also summarizes 10 recommendations from the Institute of Medicine to improve cancer care quality, such as ensuring treatment at high-volume facilities, using evidence-based guidelines, measuring quality, coordinating care, investing in research and addressing disparities.
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη ΦαρμακοεπιδημιολογίαEvangelos Fragkoulis
The document discusses the contribution of general/family medicine to pharmacoepidemiology. It describes pharmacoepidemiology as the study of drug use and effects in large populations to support rational drug use and improve health outcomes. Primary care physicians are well-positioned to identify drug safety issues and provide data from electronic health records for pharmacoepidemiology research. Routinely collected healthcare data can be used to study drug patterns, safety, and effectiveness in real-world populations.
This keynote speech was delivered by Janet Freeman-Daily to the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology on September 14, 2017.
Existing value frameworks for cancer care omit a key component: patient-defined value. This presentation looks at some patient perspectives on value found in patient-driven research, discusses the importance of shared decision making and goals of care discussions, and shares resources to help clinicians incorporate patient-defined value in cancer care.
The document discusses patient non-adherence to medical treatment plans. It summarizes research showing that healthcare providers and patients have differing views on adherence levels. The main reasons for non-adherence are identified as lack of education, forgetfulness, and cost/complexity of treatment plans. The document reports on surveys of healthcare providers and patients, finding that both groups agree responsibility for adherence is primarily on patients, but that doctors and other providers should better educate patients. Improving communication between providers and patients is seen as key to increasing treatment adherence.
This chapter discusses financing of the US healthcare system. It notes that healthcare spending has increased annually since 1960 and now accounts for nearly 18% of GDP. Funding comes from various sources including private insurance (34%), out-of-pocket payments (13%), and government programs like Medicare and Medicaid (49%). Medicare provides coverage for those over 65 and some disabled individuals, while Medicaid covers some poor populations. The money spent goes primarily towards personal healthcare services like hospital and physician care. Payment methods include fee-for-service, capitation, and value-based models. Despite high spending, over 50 million Americans still lack health insurance coverage.
This document outlines priority areas for improving quality in public health as identified by the Public Health Quality Forum. It recommends focusing on population health metrics and information technology, evidence-based practices and research/evaluation, systems thinking, and sustainability/stewardship. The goal is to build better systems to support health for all by maximizing opportunities in the Affordable Care Act and learning from quality improvement efforts in healthcare. Key strategies include coordinating efforts across sectors, focusing on prevention, and strengthening foundations for quality public health.
Oncology drug development faces challenges in demonstrating treatment "value" beyond just clinical efficacy. As cancer treatment shifts to a model of chronic disease management, stakeholders increasingly demand evidence that new drugs provide overall pharmacoeconomic benefits and improved quality of life. The emergence of value-based medicine will require redefining clinical trials to generate appropriate data on a drug's overall worth from multiple perspectives, including patients, clinicians, payers and society.
The document discusses key aspects of evaluating healthcare system performance based on three criteria: quality, equity, and efficiency. Quality is assessed by examining structure, process, and outcomes at both the clinical and population levels. Equity looks at fair access and treatment across groups. Efficiency aims to deliver services at minimum cost. Data and health information technology are critical to comprehensively measure performance over time on a national scale.
Assessment of Patients Satisfaction in Accredited and Non–Accredited Primary ...Mohammad Shishtawy
Master Thesis in Family Meidicne about Assessment of Patient Satisfaction in Accredited and Non-Accredited Primary Health Care Facilities in Nabaroh Health District
Zagazig University
2015
El documento describe varias oportunidades de negocio para una compañía de telecomunicaciones en Merida, incluyendo convertirse en un proveedor de internet, ofrecer acceso a internet de alta velocidad, rentar espacio para un datacenter, rentar espacio en la azotea para antenas celulares, proveer asistencia técnica a clientes, crear un centro de monitoreo de redes, y ofrecer servicios de diseño y construcción de redes.
Sociedad anonima y socieda de responsabilidad limitadamichellis_vivas
La asamblea general de accionistas es el órgano constituido por los accionistas o sus representantes para deliberar asuntos relacionados con la compañía. La compañía anónima es aquella en la cual las obligaciones sociales están garantizadas por un capital determinado y cuyos socios solo están obligados por el monto de su acción. La sociedad de responsabilidad limitada divide su capital en cuotas de participación no representadas por acciones negociables, y sus socios se limitan al monto suscrito mediante aportes establecidos en el contrato.
The study aimed to investigate associations between regulatory policy, workforce capacity, and health outcomes using Medicaid data from four states. However, the analysis found significant data quality issues. Key variables like service provider specialty were missing or incomplete, preventing valid conclusions about the proportion of services provided by nurse practitioners and physician assistants. At best, Alabama had 85% reporting but showed nurse practitioners and physician assistants providing significantly fewer services than medical doctors for selected chronic conditions despite making up over half of primary care workforce capacity. Overall, the Medicaid data proved inadequate for the research purposes due to inconsistent and missing coding across states.
This study assessed health care costs and utilization among union members from 2008-2010, comparing those who received primary care from providers participating in a public health initiative (PCIP) versus non-participating providers. Members accessing PCIP providers saw a 16% decrease in hospitalizations for chronic conditions, whereas non-PCIP members saw a 15% increase. PCIP access was associated with lower inpatient utilization and costs. Specialty care increased more for PCIP members with diabetes and hypertension. Overall, the results suggest population health initiatives incorporating electronic health records can reduce health care costs by decreasing hospitalizations for better chronic disease management.
Muir Gray at the First National Conference on Health Care Quality RegistersTHL
The document discusses increasing value in healthcare systems through a "Triple Value Healthcare" approach. It proposes focusing on personal value for individuals, population value for given populations, and technical value through optimizing outcomes and resource use. Key strategies include providing full information to patients, shifting resources from overused to underused areas, developing population-based systems and networks, and creating a culture of stewardship. The goal is to improve outcomes while making the best use of limited resources.
This document discusses the role of pharmacists in public health. It begins by outlining objectives related to identifying pharmacists' functions in public health, explaining their relevance and involvement, and listing health challenges. It then provides historical context of pharmacists' education in public health from 1932-2010. The document poses four questions to consider pharmacists' roles, including whether there is an unmet public health need pharmacists could fill. It argues pharmacists have skills to address issues like medication safety and management. Statistics on medication use and issues in the US demonstrate an unmet need pharmacists are well-suited to address.
The Precision Medicine Initiative is a $215 million effort to revolutionize disease treatment through personalized care. It will create a voluntary national research cohort of over 1 million Americans to share health data to accelerate discoveries. The goals are to develop more effective cancer treatments through genetic testing and clinical trials, create an open research platform for the cohort to partner on studies, and ensure strong privacy protections for health information. The initiative aims to translate precision medicine successes into broader application through public-private partnerships and regulatory modernization.
The goal of this webinar was to help healthcare professionals improve care coordination for patients with advanced illness and to reduce hospital readmissions and length of stay.
The goal of this webinar is to help hospice and healthcare professionals understand the history, philosophy and practice of hospice care and palliative care, including common myths and misconceptions, common diagnoses for hospice referrals, identification of hospice-eligible patients, reimbursement for hospice services, and the benefits of advance care planning and early referrals.
The document discusses Quality Use of Medicines (QUM), which aims to ensure optimal health outcomes from medication use. QUM focuses on selecting management options wisely, choosing suitable medicines appropriately, and using medicines safely and effectively. The National Medicines Policy also aims to ensure timely access to medicines, quality products, quality use, and a viable medicines industry. Key partners in achieving QUM include healthcare providers and recipients, as well as governments, industry, and educators.
Reducing Readmissions and Length of Stay | VITAS HealthcareVITAS Healthcare
Hospice can help reduce hospital readmissions and lengths of stay for patients with serious illnesses like heart failure. By providing comprehensive care, including nursing support 24 hours a day, palliative care physician support, medications, equipment, and targeted programs for conditions like CHF, hospice can help meet patient goals of comfort and avoiding inappropriate hospitalizations. For the patient with heart failure described in the case study, hospice could help prevent readmissions and allow the patient to focus on quality of life rather than further medical interventions by providing end-of-life care in their home.
The demand for healthcare services is driven by both consumption and investment motives. As consumption goods, healthcare makes people feel better, and as investment goods, better health increases productivity. Patients rely on healthcare professionals to evaluate their needs and make decisions. Demand is influenced by income, price, education, marital status, age, gender, access to facilities, household size, and insurance coverage. Higher incomes, education, prices, and insurance increase demand, while single and older individuals also tend to use more services.
This document discusses pharmacology in the sexual health setting. It focuses on developing knowledge to safely administer prescribed and nurse-initiated medications commonly used to treat STIs. Key points include understanding STI natural histories, assessing clients for medication administration, and ensuring quality use of medicines by selecting options wisely, choosing suitable medications, and using medications safely and effectively. Nurses must be familiar with medication actions, contraindications, and guidelines for administration.
The document discusses quality cancer care and outlines several principles and recommendations. It presents 12 principles for quality cancer care established by the National Coalition for Cancer Survivorship, including the rights of cancer patients and survivors to access affordable care, clinical trials, psychosocial services and follow up care. It also summarizes 10 recommendations from the Institute of Medicine to improve cancer care quality, such as ensuring treatment at high-volume facilities, using evidence-based guidelines, measuring quality, coordinating care, investing in research and addressing disparities.
Η συνεισφορά της Γενικής Οικογενειακής Ιατρικής στη ΦαρμακοεπιδημιολογίαEvangelos Fragkoulis
The document discusses the contribution of general/family medicine to pharmacoepidemiology. It describes pharmacoepidemiology as the study of drug use and effects in large populations to support rational drug use and improve health outcomes. Primary care physicians are well-positioned to identify drug safety issues and provide data from electronic health records for pharmacoepidemiology research. Routinely collected healthcare data can be used to study drug patterns, safety, and effectiveness in real-world populations.
This keynote speech was delivered by Janet Freeman-Daily to the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology on September 14, 2017.
Existing value frameworks for cancer care omit a key component: patient-defined value. This presentation looks at some patient perspectives on value found in patient-driven research, discusses the importance of shared decision making and goals of care discussions, and shares resources to help clinicians incorporate patient-defined value in cancer care.
The document discusses patient non-adherence to medical treatment plans. It summarizes research showing that healthcare providers and patients have differing views on adherence levels. The main reasons for non-adherence are identified as lack of education, forgetfulness, and cost/complexity of treatment plans. The document reports on surveys of healthcare providers and patients, finding that both groups agree responsibility for adherence is primarily on patients, but that doctors and other providers should better educate patients. Improving communication between providers and patients is seen as key to increasing treatment adherence.
This chapter discusses financing of the US healthcare system. It notes that healthcare spending has increased annually since 1960 and now accounts for nearly 18% of GDP. Funding comes from various sources including private insurance (34%), out-of-pocket payments (13%), and government programs like Medicare and Medicaid (49%). Medicare provides coverage for those over 65 and some disabled individuals, while Medicaid covers some poor populations. The money spent goes primarily towards personal healthcare services like hospital and physician care. Payment methods include fee-for-service, capitation, and value-based models. Despite high spending, over 50 million Americans still lack health insurance coverage.
This document outlines priority areas for improving quality in public health as identified by the Public Health Quality Forum. It recommends focusing on population health metrics and information technology, evidence-based practices and research/evaluation, systems thinking, and sustainability/stewardship. The goal is to build better systems to support health for all by maximizing opportunities in the Affordable Care Act and learning from quality improvement efforts in healthcare. Key strategies include coordinating efforts across sectors, focusing on prevention, and strengthening foundations for quality public health.
Oncology drug development faces challenges in demonstrating treatment "value" beyond just clinical efficacy. As cancer treatment shifts to a model of chronic disease management, stakeholders increasingly demand evidence that new drugs provide overall pharmacoeconomic benefits and improved quality of life. The emergence of value-based medicine will require redefining clinical trials to generate appropriate data on a drug's overall worth from multiple perspectives, including patients, clinicians, payers and society.
The document discusses key aspects of evaluating healthcare system performance based on three criteria: quality, equity, and efficiency. Quality is assessed by examining structure, process, and outcomes at both the clinical and population levels. Equity looks at fair access and treatment across groups. Efficiency aims to deliver services at minimum cost. Data and health information technology are critical to comprehensively measure performance over time on a national scale.
Assessment of Patients Satisfaction in Accredited and Non–Accredited Primary ...Mohammad Shishtawy
Master Thesis in Family Meidicne about Assessment of Patient Satisfaction in Accredited and Non-Accredited Primary Health Care Facilities in Nabaroh Health District
Zagazig University
2015
El documento describe varias oportunidades de negocio para una compañía de telecomunicaciones en Merida, incluyendo convertirse en un proveedor de internet, ofrecer acceso a internet de alta velocidad, rentar espacio para un datacenter, rentar espacio en la azotea para antenas celulares, proveer asistencia técnica a clientes, crear un centro de monitoreo de redes, y ofrecer servicios de diseño y construcción de redes.
Sociedad anonima y socieda de responsabilidad limitadamichellis_vivas
La asamblea general de accionistas es el órgano constituido por los accionistas o sus representantes para deliberar asuntos relacionados con la compañía. La compañía anónima es aquella en la cual las obligaciones sociales están garantizadas por un capital determinado y cuyos socios solo están obligados por el monto de su acción. La sociedad de responsabilidad limitada divide su capital en cuotas de participación no representadas por acciones negociables, y sus socios se limitan al monto suscrito mediante aportes establecidos en el contrato.
Rinconada reliability saratoga council presentation 10 7-15 v3Rishi Kumar
This presentation provides information about the Rinconada Reliability Project, which aims to upgrade the Rinconada Water Treatment Plant. The project will replace facilities that are nearing the end of their useful life, increase water production capacity, and help meet water quality and seismic standards. It will be completed in five phases from 2015 to 2020 and includes improvements like raw water ozonation, flocculation, filtration, and a new operations building. Stay updated by visiting the project website or contacting the listed public affairs representative.
FELIZ DÍA DE LAS MADRES Y GRACIAS POR HACERNOS TAN FELICES Andres Galeano
EL FIN DE ESTA TARJETA ES RESALTAR LA LA IMPORTANCIA, EL AFECTO Y EL AGRADECIMIENTO A NUESTRAS MADRES DEL CENTRO POBLADO DE CACHIPAY, QUE DIOS LAS PROTEJA Y LAS BENDIGA SIEMPRE.
The CEO of DEWA and the President of General Electric Gulf discussed developments in energy transformation and renewable energy. They reviewed DEWA's current and ongoing projects and discussed efforts to develop new technologies. The President of GE Gulf outlined solutions and techniques offered by GE for renewable energy, technology, and investments.
FusionInventory has grown significantly in its first year, with nearly 50 contributors and up to 3,000 daily users. The agent has been stable for Linux/Unix/Mac systems and supports new features like HTTPS and UTF-8. Version 3.0 is being rewritten for lower memory usage. Plugins have been developed for GLPI including hardware/software inventory, network discovery, and upcoming deployment capabilities. Self-contained agents support over 50 systems and are rebuilt hourly for easier deployment. The project aims to improve testing, documentation, and integration with GLPI.
This document contains a series of photo credits from various photographers. The photos were likely used in a Haiku Deck presentation about being inspired that was shared on SlideShare. The presentation encouraged viewers to create their own Haiku Deck presentations.
The document summarizes a health consumerism survey conducted in North Texas. The survey aimed to understand patient preferences and experiences accessing healthcare. It collected both qualitative and quantitative data through an online and paper-based questionnaire distributed across Tarrant County. Key findings included high levels of patient satisfaction overall with provider communication and care coordination. However, some areas for improvement were identified such as encouraging patients to ask questions and using visual aids. The survey also found that the majority of respondents were not willing to have someone monitor their medications due to privacy concerns. Education levels did not impact understanding of provider explanations. The results provide insights into patient behaviors and opportunities to further engage consumers in their healthcare.
Building Patient-Centeredness in the Real World: The Engaged Patient and the ...EngagingPatients
This paper examines the separate but intertwined ethical, economic and clinical concepts of patientcenteredness and how ACOs provide a structure for turning those concepts into a functioning reality.
Global Medical Cures™ | Paving way for Personalized Medicine (2013) Global Medical Cures™
Global Medical Cures™ | Paving way for Personalized Medicine (2013)
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Pharmaceutical Industry's Role in Advancing Precision MedicineClinosolIndia
The pharmaceutical industry plays a pivotal role in driving advancements in precision medicine, a revolutionary approach that tailors medical treatment to individual patient characteristics. By leveraging cutting-edge technologies, conducting innovative research, and collaborating with diverse stakeholders, the pharmaceutical sector contributes significantly to the development and implementation of precision medicine, ushering in a new era of personalized healthcare.
2016 16th population health colloquium: summary of proceedings Innovations2Solutions
The document summarizes the key discussions and presentations from the 2016 Sixteenth Population Health Colloquium. The Colloquium focused on challenges in implementing population health strategies and achieving the goals of the Affordable Care Act. Key topics included understanding patient fear, creating a new population health protection agenda to reduce costs, using data and technology to improve care for older adults, and engaging consumers in wellness programs. Presenters emphasized the need for collaborative, integrated care and addressing social determinants of health to improve population health outcomes and control rising healthcare costs.
HeadnoteGovernments with universal healthcare systems are increa.docxisaachwrensch
Headnote
Governments with universal healthcare systems are increasingly bemoaning the costs of their systems and the need to contain these costs if affordable healthcare services are to be sustained into the future. In a bid to reduce the costs of healthcare, politicians and bureaucrats have championed the need for reform. Although avoiding the language of rationing, the kinds of 'reforms' being championed (eg. greater government regulation of universal health coverage, reducing reimbursement for medical costs, cutting funding to public hospitals) seem however, to be more concerned with restricting universal healthcare coverage, rather than reforming it.
The rhetoric of healthcare reforms has also had a political ideological objective shifting the provision of and accountability for public healthcare services to private sector providers. This objective has been pursued despite experts warning that such a shift will ultimately lead (and in some cases has already led) to inequities and unjust disparities in access to healthcare and related health outcomes, especially in vulnerable populations who cannot afford private health insurance.
Australia has not been immune from ideologically driven machinations about the sustainability of its universal healthcare scheme, ie. Medicare. Despite health expenditure in Australia reportedly reaching a record low for the period 2012-2013, there has been a political campaign of spreading false and misleading information about Medicare's sustainability (Keast 2015).This misinformation has included 'blaming' vulnerable populations (eg. an ageing demographic, the 'undeserving poor') for their allegedly disproportionate over-utilisation of public healthcare services and the need to curb this costly 'wanton' demand. What has been overlooked in this situation, however, is that a key driver of the spiraling costs of healthcare is not the over-utilisation of services by people in need, but rather 'the use of wasteful tests and treatments' prescribed by doctors (Tilburt & Cassel, 2013) together with the rising costs of drugs (driven by the business behaviours of the pharmaceutical industry) and medical technology, particularly in hospitals. Also overlooked is the problem of language and the tendency to treat the terms 'healthcare', 'hospital care', and 'medical care' as being synonymous, when they are not. Failure to distinguish what each of these terms refers to unnecessarily muddles debate about what healthcare reforms are needed as well as where and how these should occur.
Question of nursing ethics
The ethics of healthcare rationing has been the subject of debate for decades. This debate has primarily rested on the issue of whether it is ever acceptable to ration healthcare and, if so, on what grounds. It has also prompted unresolved controversies about the interests of individuals versus the collective interests of society in accessing limited healthcare resources and how best to balance these competing inter.
This document discusses insights from a survey of 342 physicians on their perspectives of the pharmaceutical industry. It finds that while recent controversies have eroded public trust in pharma, physicians still see the industry as partners in patient care. However, many physicians feel their decision-making has been constrained by insurers and regulators. The top constraint cited is insurance companies, as their reimbursement policies dictate approved therapies. The FDA is also cited for its narrow drug approvals. Pharma is less blamed, with physicians wanting more open dialogue and information from companies.
The pharmaceutical industry has made it very difficult to know what the clinical trial evidence actually is regarding psychotropics. Consequently, primary care physicians and other front-line practitioners are at a disadvantage when attempting to adhere to the ethical and scientific mandates of evidence based prescriptive practice. This article calls for a higher standard of prescriptive care derived from a risk/benefit analysis of clinical trial evidence. The authors assert that current prescribing practices are empirically unsound and unduly influenced by pharmaceutical company interests, resulting in unnecessary risks to patients. In the spirit of evidenced based medicine’s inclusion of patient values as well as the movement toward health home, we present a patient bill of rights for psychotropic prescription. We then offer guidelines to raise the bar of care equal to the available science for all prescribers of psychiatric medications.
Essay on Definitions of Health
Healthcare in the United States Essay
Why Is Healthcare Important? Healthcare?
Essay On Healthcare System
Essay On Impact On Health Care
Essay On Home Health Care
Essay On Affordable Health Care
Health Care Persuasive Essay
Essay on Careers in Healthcare
Essay On Health Care
Persuasive Essay On Health Care
Essay On Healthcare In The United States
Inequality in Healthcare Essay examples
Health Care Trends Essay examples
Social Media And Health Care Essay
Essay on Quality Health Care
Essay on Health Care
The Health Of A Health Care System
Essay On Health Care
Persuasive Essay On Health Care
This white paper explores how public and private bodies in the UK could work together to accelerate the development and adoption of personalized medicine through strategic alliances. Personalized medicine involves classifying individuals into disease subpopulations to identify who will benefit most from specific treatments. The paper recommends that the UK focus on personalized medicine approaches for several diseases areas, and establish partnerships and initiatives to advance the necessary biomarkers and technologies.
Precision Medicine: Four Trends Make It PossibleHealth Catalyst
When realized, the promise of precision medicine (to specifically tailor treatment to each individual) stands to transform healthcare for the better by delivering more effective, appropriate care. To date, to achieve precision medicine, health systems have faced financial, data management, and interoperability barriers. Current trends in healthcare, however, will give researchers and clinicians the quality and breadth of health data, biological information, and technical sophistication to overcome the challenges to achieving precision medicine.
Four notable trends in healthcare will bolster to growth of precision medicine in the coming years:
Decision support methods harness the power of the human genome.
Healthcare leverages big data analytics and machine learning.
Reimbursement methods incentivize health systems to keep patients well.
Emerging tools enable more data, more interoperability.
Forty years ago, the Region of the Americas played a critical JeanmarieColbert3
Forty years ago, the Region of the Americas played a critical role in the develop-
ment and negotiation of the Alma-Ata Declaration, which identified primary health
care as a central strategy to the goal of health for all and a comprehensive approach to
the organization of health systems. Since then, the values and principles of primary
health care, which include the right to health, equity, solidarity, social justice and par-
ticipation, and multisectoral action, among others, have formed the basis of many
PAHO mandates and have guided health systems transformation in the Region. The
positive impact of primary health care on the reduction of mortality, morbidity, and
inequities in health is well known. (1) What’s more, primary health care consumes less
financial resources than curative approaches and promotes a chain of positive results
from improved health to increased economic output, growth and productivity. (2)
In 2007, PAHO’s position paper on Renewing Primary Health Care in the Americas
included the definition of elements and functions of a primary healthcare-based
health system with the intention of providing guidance to countries as they worked
to transform their systems. (3) In 2014, the 53rd PAHO Directing Council’s resolution
on Universal Access to Health and Universal Health Coverage (4) recognized the
values and principles of Alma-Ata. The resolution urged PAHO Member States to
promote intersectoral action to address social determinants of health and move
toward health systems where all people and communities have access, without any
discrimination, to comprehensive, appropriate and timely, quality health services, as
well as access to safe, effective, and affordable quality medicines, while ensuring that
the use of such services does not expose users to financial difficulties. (4) The Sustai-
nable Health Agenda for the Americas 2018–2030, which represents the commitment
of Member States to the 2030 Agenda for Sustainable Development and unfinished
business from previous engagements, established areas of action that reinforce and
complement the recommendations of the Alma-Ata Declaration. These include stren-
gthening the national health authority; tackling health determinants; increasing so-
cial protection and access to quality health services; diminishing health inequalities
among countries and inequities within them; reducing the risk and burden of disease;
strengthening the management and development of health workers; harnessing
knowledge, science, and technology; and strengthening health security. (5)
In the Region, the lessons that have been learned about the primary health care
approach since Alma-Ata have been overwhelmingly positive. We have seen that
countries that have implemented policies and programs based on primary health
care have registered the lowest levels of infant and maternal mortality. Other achie-
vements include improvement in public spending, increase in primary care s ...
Dr Dev Kambhampati | FDA- Paving the Way for Personalized MedicineDr Dev Kambhampati
This document discusses personalized medicine from a regulatory perspective. It begins by defining personalized medicine as tailoring medical treatment to an individual's characteristics, needs, and preferences. The concept has existed for hundreds of years but recent advances in genomics, medical imaging, and other areas now enable a more personalized approach. The FDA plays a unique role in advancing personalized medicine by helping to bring these new medical products to market and evolving its regulatory processes in response to scientific developments. The document outlines FDA's efforts to define regulatory pathways, collaborate on research, and apply new knowledge to product reviews to help usher in this new era of individualized healthcare.
This document discusses the history of the healthcare system in the US and the changing role of physicians within that system. It notes that physicians originally had close personal relationships with patients but that hospitals and specialization led to more fragmented care. Government programs like Medicare and the rise of managed care further changed the physician role by increasing administrative duties. The document examines the current medical school curriculum, noting a lack of leadership and management training. It discusses some programs that do offer such training but notes they are electives, not mandatory. The document concludes there are gaps in preparing physicians for the changing healthcare system and future skills needed in areas like business, communication, and leadership.
This document discusses health economics. It begins by defining health economics as relating to efficiency, effectiveness, value and behavior in the production and consumption of health and healthcare. It then discusses key features of health economics, including the role of doctors as both suppliers and users of healthcare, the lack of consumer experience in healthcare, views of health as a right, and the unpredictability of disease. The document goes on to discuss the importance of health economics and the expansion of the field over time, evidenced by growing research, journals, and improvements in health and longevity globally.
From surviving to thriving: cancer’s next challengePwC Russia
Рак-диагноз, который никто не хочет услышать. Приуроченный к Всемирному дню борьбы с раком отчет PwC рассказывает об историях тех, кто пережил этот страшный период жизни и не сдался.
Applications of statistics in medical Research and HealthrMuhammadNafees42
This will help you to understand the applications of basic statistics.The application of stat in medical health and research.
#nafeesupdates
#nafeesmedicos
Three key trends are forcing a change in today's health models: 1) Rising chronic diseases among both young and old are driving up health costs and creating future liabilities. 2) Technology is enabling mass customization of healthcare similar to other industries. 3) Broader factors like behavior, socioeconomics, and genetics are recognized as influencing health beyond medical care. To address these issues, health will be customized around six vectors: incentives, regulations, funding, patient communication, information technology, and workforce models to personalize diagnosis, care and cure for individuals.
The December edition of the Professional Diversity Network Jobs Index & Report focuses on the Healthcare sector and the position of the diverse employee and candidate in this rapidly growing segment of the US economy.
The ethics of performance monitoring-private sector perspectiveDavid Quek
Increasingly medical practice is coming under intense scrutiny as to what is appropriate and affordable care, including serious considerations of patient safety issues and protection. Medical professionalism must be consciously adhered to as we try and find the best health care for our patients at the best value and outcomes for our patients themselves, and also for society at large. In view of escalating health care costs, physician autonomy to practice as he or she likes or deems fit has now come under siege with more and more performance monitoring, not just for appropriateness, but also for outcomes, necessity and cost-effectiveness. Physician' vested interests must be tempered with evidence-based benefits or at least be associated with no increase in harm or incur affordability issues. Fraudulent physician malfeasance are now being uncovered via whistle-blowers, or through greater more meticulous audit of various validated performance measures, and those physicians found to have flouted these due to pecuniary self-interests, overuse of tests or procedures have been found guilty and sanctioned with heavy fines, return of reimbursements as well as imprisonment, and erasure from medical registries and the removal of license to practice.
5. 5
Dear Colleague:
When, in his State of the Union Address, President Obama called for a “Precision Medicine
Initiative” that would, he said at a White House ceremony 10 days later, unleash “one of the
greatest opportunities for new medical breakthroughs that we have ever seen,” he underscored
PMC’s ongoing contention that a new era in medicine is within our reach. If we invest wisely
in research and put in place new and carefully calibrated systems to ensure that government
keeps pace with emerging science and technology, we can, he noted, improve both patient
care and the efficiency of the health care system.
But the President also recognized a second reality, which is that this paradigm shift will
not happen just because the science and new technologies suggest it should. This is the reality
on which the Coalition has built its portfolio of activities.
The President’s program has four parts, which include: increased funds for the National Cancer
Institute to study the genetic factors that cause cancer; the creation of a “voluntary national
research cohort” of one million Americans who would share genomic data, lifestyle information,
electronic health records and biological information in order to answer questions about wellness
and disease; additional funds for the Food and Drug Administration to update its ability to regulate
personalized medicine technologies; and, not least, more financial support for the Office of the
National Coordinator to develop interoperability standards to secure the exchange of health
data across systems.
In brief, the President has recognized, as PMC has contended since it was publicly launched
in 2004, that a move from one-size-fits-all/trial-and-error medicine to health care based on an
understanding of individual variation necessitates systems-level change. In addition to further
understanding the biological basis of patient heterogeneity, it requires a willingness to recon-
sider and reform the intervening variables impacting the delivery of new treatments to patients,
which include regulation, reimbursement and education. Through these efforts, we can provide
better health care solutions, including enhanced abilities to predict and prevent disease, per-
sonalize treatments, and develop a more value-oriented health system.
PMC had tremendous success promoting this agenda in 2015. Having organized all of the
stakeholders around the world with an interest in advancing personalized medicine, the Coali-
tion’s voice is sought out and respected — by government as well as health care manufacturers
and providers, which, like government, are required to alter their systems to keep up with
changing science and technology.
Like PMC itself, this report is focused on three themes: education, advocacy and impact.
We invite you to read it and share with us your thoughts as we move into the second decade
of promoting personalized medicine so that both patients and our health system benefit from
improved clinical care and increased overall value.
We believe that this is the future of medicine, and are committed to getting us there.
Sincerely yours,
Edward Abrahams, Ph.D. William Dalton, Ph.D., M.D.
President Chair of the Board
6. 6
Personalized medicine is an evolving
field in which physicians use diagnos-
tic tests to determine which medical
treatments will work best for each
patient. By combining the data
from those tests with an individual’s
medical history, circumstances and
values, health care providers can
develop targeted treatment and
prevention plans.
— PMC’s definition of personalized medicine
7. 7
House of Representatives Subcommittee on
Health, just hours after the subcommittee’s
mark-up of the 21st Century Cures draft bill
on May 14.
Burgess identified and analyzed several of the
most pressing policy issues in the field. He
drew the audience’s attention in particular to
the interoperability provisions in the Cures bill,
which align with concepts in President Obama’s
Precision Medicine Initiative, and presented
himself as an advocate for innovation in labo-
ratory-developed testing and a champion of
participatory research.
Nearly 200 personalized medicine stakeholders
attended the event, which took place at the
National Press Club in Washington, D.C.
Educating stakeholders is of paramount importance to personalized medicine’s success.
A 2014 survey by the Coalition revealed that 62 percent of Americans have never heard
of personalized medicine, and data from the communications firm CAHG suggests that
only 20 percent of physicians have any training in how to administer it. In 2015, PMC
acted to define the field, uncover the challenges and outline solutions for stakeholders
throughout the health care system.
Defining the Field
The 11th Annual State of Personalized
Medicine Luncheon Address
Like previous iterations of the event, this
year’s State of Personalized Medicine Address
served as a forum at which PMC members and
guests from across the health care community
engaged policy leaders in a discussion of the
key issues facing the field, solidifying PMC’s role
as, in Pfizer Chairman of the Board and CEO
Ian Read’s words during this year’s event, “the
one place where innovators, scientists, patients,
providers and payers all come together to
collaborate, debate and educate the public and
the private sectors.”
Following an introduction from Read, this year’s
address was delivered by the Honorable Michael
C. Burgess, M.D. (R-TX), a member of the U.S.
EDUCATION
8. 8
Personalized Medicine: Improving Patient
Care in the 21st Century
As the U.S. Senate began to examine its prior-
ities in personalized medicine following the
passage of the 21st Century Cures Act by the
U.S. House of Representatives Energy and
Commerce Committee, the Honorable Amy
Klobuchar (D-MN) recognized a need to
educate her colleagues in the Senate.
The Coalition responded by organizing a Hill
briefing titled Personalized Medicine: Improving
Patient Care in the 21st Century, which convened
more than 125 individuals, including more
than 50 Congressional staffers, in the Kennedy
Caucus Room of the Russell Senate Office
Building on July 16. The briefing was co-hosted
by Senators Klobuchar and Orrin Hatch (R-UT).
Designed to provide an overview of what
personalized medicine is and why it is important,
the event featured introductory remarks from
Klobuchar and Stephanie Haney, a stage IV lung
cancer patient, as well as comments from a
panel of experts from among PMC’s membership.
Keith Stewart, M.B., Ch.B., director of Mayo
Clinic’s Center for Individualized Medicine, Greg
Keenan, M.D., vice president of medical affairs
and U.S. head medical officer at AstraZeneca,
and Michael Pellini, M.D., CEO of Foundation
Medicine, joined Kathy Hudson, Ph.D., deputy
director for science, outreach and policy at the
National Institutes of Health (NIH), on a panel
that explored how the field is progressing in an
era of constrained resources.
EDUCATION I PMC 2015 ANNUAL REPORT
9. 9
Personalized Medicine’s Benefits
2X 15% 30%
Following introduction
of imatinib, a targeted
therapy
Following discovery of
molecular receptors
associated with tumor
growth
Documented when
genetic information was
used in dosing warfarin
PMC presented Congressional staffers with statistics on personalized medicine’s
potential in July.
34% $604M 17K
Source: Personalized Medicine 101: Improving Patient Care in the 21st Century. PMC, 2015.
PERSONALIZED MEDICINE IMPROVES
HEALTH OUTCOMES
PERSONALIZED MEDICINE CAN MAKE THE
HEALTH SYSTEM MORE EFFICIENT
Myelogenous Leukemia
5-year Survival Rate
Colorectal Cancer
5-year Survival Rate
Heart Patient
Hospitalization Rate
Chemotherapy Use
If women with breast
cancer received genetic
testing prior to treatment
If metastatic colorectal
cancer patients recieved
genetic testing prior to
treatment
If a genetic test was
used to properly dose
blood thinners
Colorectal Cancer Costs Strokes Prevented
10. A New Landscape for the
Pharmaceutical Industry
of all drugs in
development are
personalized medicines.
of oncology drugs
in development are
personalized medicines.
PMC research illustrates the biopharmaceutical industry’s deep
commitment to personalized medicine.
Source: Biopharmaceutical Companies’ Personalized Medicine Research Yields Innovative Treatments for Patients.
PMC/PhRMA, 2015.
137
73%42%
13%
Personalized medicines
represent 13% of all
approved medicines.
approved medicines have
genomic information in
their label.
11. 11
Uncovering the Challenges
PMC Report: Industry is Investing in
Personalized Medicine Despite Obstacles
in Science, Regulation and Reimbursement
An article on the promise of personalized medi-
cine published in the Harvard Business Review in
2007 identified the pharmaceutical industry’s
reluctance to abandon the “blockbuster” drug
development model, which favors the develop-
ment of drugs for as broad a patient group as
possible, as a barrier to the advancement of the
field. With its finger on the pulse of the industry,
PMC recently decided to test that widely
accepted contention, collaborating with the
Tufts Center for Drug Development to docu-
ment the level of commitment to personalized
“Companies are confounded when regulatory and payment policies do not support
targeted therapies. The science is so hard and the benefit to patients so striking that
the rest should naturally follow, in the eyes of the developers.”
— PMC Executive Vice President Amy M. Miller, Ph.D., in GenomeWeb, May 20, 2015
medicine on the part of the pharmaceutical
and diagnostics industries.
The findings, which were released in May of this
year, demonstrate that although the industry is
increasing its investment in targeted therapies,
challenges in science, regulation and reimburse-
ment still concern executives.
“Companies are confounded when regulatory
and payment policies do not support targeted
therapies,” PMC Executive Vice President Amy
M. Miller, Ph.D., told GenomeWeb. “The science
is so hard and the benefit to patients so striking
that the rest should naturally follow, in the eyes
of the developers.”
PMC 2015 ANNUAL REPORT I EDUCATION
12. 12
Outlining the Solutions
Integrating Personalized Medicine into
Health Care: The 2nd PMC/BIO Solutions
Summit
Through conversations with members in
the provider community, PMC has recognized
the need to determine the best practices to
integrate personalized medicine into clinical
care. In October, the Coalition co-hosted the
2nd PMC/BIO Solutions Summit, Integrating
Personalized Medicine into Health Care, to orga-
nize the community’s thinking on this topic.
Convened by PMC and the Biotechnology
Industry Organization (BIO), the conference
demonstrated how the right combination of
education initiatives, state-of-the-art infra-
structure and appropriate incentives can facil-
itate the adoption of personalized approaches
to clinical care. The discussion suggested that
education efforts should focus in particular on
the value of personalized medicine; infrastruc-
ture should allow for the management of large
amounts of data; and incentives should reward
improved outcomes.
EDUCATION I PMC 2015 ANNUAL REPORT
13. 13
Principles for Integrating Personalized
Medicine Into Health Care
The PMC/BIO Solutions Summit demonstrated that integrating
personalized medicine into a health care system requires initiatives
to educate providers, policymakers and patients; state-of-the-art
IT and program operations infrastructure; and incentives to use per-
sonalized clinical approaches to care.
INTEGRATION
INFRASTRUCTURE INCENTIVES
EDUCATION
14. 14
“Personalized medicine is transforming
the practice of medicine, and the
Personalized Medicine Coalition
is playing a critical role in bringing
together all of the stakeholders to
help make that happen.”
— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor
of Genetics, Harvard Medical School
15. 15
Incentivizing Innovation
Comment Letter on the U.S. Senate HELP
Committee’s Innovation for Healthier
Americans Initiative
When the U.S. Senate Health, Education, Labor &
Pensions (HELP) Committee solicited comments
in its Innovation for Healthier Americans white
paper, which was released in January, PMC urged
the committee to ensure that personalized medi-
cine is considered as the initiative moves forward.
“Our interest in the Healthier Americans initia-
tive pertains to how personalized medicine can
benefit the health care system by improving
the quality, safety, accuracy and effectiveness
of treatments,” PMC’s comment letter to the
committee reads. “Furthermore, health care
system spending can be reduced as considerable
resources spent on ineffective treatments for a
particular patient as well as the associated costs
for visits to the doctor and hospital are avoided.”
In its comment letter, which was submitted in
February, PMC advocated for policies that:
1. Incentivize the development of new, person-
alized approaches to care
2. Establish a predictable and flexible regulatory
system that is responsive to new scientific
discoveries
3. Encourage health care innovations through
proactive coverage and payment systems.
ADVOCACY
Guided by the recognition among its members that science, regulation and reimbursement
are the key challenges facing personalized medicine, PMC continued to champion
policies to incentivize innovation, modernize regulation and rethink reimbursement in 2015.
16. 16
Modernizing Regulation
Comment Letter on FDA’s Framework for
Laboratory-Developed Test Regulation
Following FDA’s release of a proposed frame-
work for regulating laboratory-developed
tests (LDTs) in July of 2014, PMC convened a
working group of members to discuss strat-
egies to ensure that the framework would not
have an adverse impact on the development
of innovative LDTs that contribute to person-
alized medicine’s advancement. The group’s
work product was finalized and submitted to
FDA as a comment letter in February.
The letter recommends that FDA refine its
proposal, publish a new draft of the framework
and collect additional feedback from the public
prior to implementation. Specifically, the letter
indicates that an updated draft should include:
• Additional details on how FDA will classify
different types of LDTs
• Clarification on how FDA’s new regulatory
practices harmonize with regulations already
in place at the Centers for Medicare &
Medicaid Services (CMS)
“It is clear that, at the very least, a second draft
of the framework should be issued together with
draft guidance documents clarifying the missing
pieces for the review and public engagement
process to be complete,” the letter reads.
ADVOCACY I PMC 2015 ANNUAL REPORT
Comment Letter on FDA’s Consideration
of the Oversight of Next-Generation
Sequencing
In December of 2014, FDA began exploring
an initiative that would dramatically alter the
landscape for personalized medicine regulation
— the oversight of next-generation sequencing
technologies. PMC worked with its members to
draft a comment letter in response to FDA’s
preliminary paper on the topic, which was sent
to the agency in March. The letter urges FDA
to be thoughtful in approaching the topic.
“We urge the agency to take the time necessary
to get [next-generation sequencing oversight]
right,” the letter reads. “Future investment in the
field depends on clear, reasonable guidelines,
which are in our power to develop now.”
The letter also outlines three key principles
for FDA to consider as it moves the initiative
forward, reminding the agency that:
• Next-generation sequencing information must
be accurate and reliable
• Patients should be assured optimal access to
these state-of-the-art technologies
• It is important to continue to work with all
stakeholders to develop important details
on how such an oversight system would be
resourced, standardized and administered.
17. 17
The Need for a
Thoughtful Approach
In comment letters this year, PMC encouraged FDA to be
thoughtful in its approach to regulating laboratory-developed
tests (LDTs) and next-generation sequencing (NGS).
JULY 2014 FDA releases proposed framework for
regulating LDTs
DECEMBER 2014 FDA releases preliminary paper on NGS
regulation
FEBRUARY 2015 PMC suggests that “at the very least,
a second draft of the [LDT] framework
should be issued for the review and public
engagement process to be complete.”
MARCH 2015 PMC urges the agency to “take the time
necessary to get [NGS oversight] right.”
18. Challenging Assumptions
The Coalition’s 2015 white paper highlighted the results of
a UnitedHealthcare pilot study suggesting that increased
spending on drugs does not necessarily lead to an increase
in total costs — in fact, the opposite may be true.
Approximately $40,000 was saved per chemotherapy patient despite
spending more on chemotherapy drugs
AFTER THREE YEARS
34%reduction in cancer treatment cost
179%spending increase
on chemotherapy drugs
19. 19
Rethinking Reimbursement
Paying for Personalized Medicine: How
Alternative Payment Models Could Help
or Hinder the Field
Following the U.S. Department of Health and
Human Services’ announcement that it plans
to tie 50 percent of traditional, fee-for-service
Medicare payments to alternative payment
models (APMs) by 2018, PMC drew attention to
how APMs could impact personalized medicine
in its white paper titled Paying for Personalized
Medicine: How Alternative Payment Models Could
Help or Hinder the Field. The paper reminds
stakeholders that depending on how they are
structured, APMs could accelerate or stifle
personalized medicine’s progress.
“Understanding each type of APM, and how it
affects both the utilization and development
of innovative treatments for complex diseases,
is key to understanding the implications of
APMs for personalized medicine,” the paper reads.
Through an exploration of accountable care
organizations (ACOs), “bundled payments” and
medical homes, the paper uncovers factors that
are essential to the future development of
APMs. These factors include:
• The degree of transparency in the develop-
ment of APMs
• The role of informed decision-making based
on research in genomics and other areas
• The use and appropriate weighting of clin-
ical quality measures that are focused on
outcomes
• The structure of provider financial incentives
that support patient choice
• The inclusion of mechanisms to recognize and
encourage appropriate adoption of personal-
ized medicines
The Centers for Medicare Medicaid Services
(CMS) Acting Administrator Andy Slavitt
responded to the Coalition’s concerns about
the structure of APMs in June, indicating in a
letter to PMC that CMS plans to put policies
in place that protect the use of “new, break-
through technologies.”
PMC 2015 ANNUAL REPORT I ADVOCACY
20. 20
“[PMC is] the one place where
innovators, scientists, patients,
providers and payers all come
together to collaborate, debate
and educate the public and
private sector.”
— Ian C. Read, Chairman of the Board
and CEO, Pfizer
21. 21
Getting Noticed
Spotlighting the Field
Through its education and advocacy efforts,
the Coalition has earned a place among the
most influential organizations in personalized
medicine policy. In addition to having its online
content cited last year during the Subcommittee
on Health hearing referenced above, PMC
President Edward Abrahams, Ph.D., participated
in a roundtable discussion on personalized
medicine with members of the U.S. House
Energy and Commerce Committee during
the committee’s effort to develop the 21st
Century Cures Act that was passed by the House
in 2015. The Coalition is routinely consulted for
comments on personalized medicine issues,
and has been featured in more than 40 news
stories about personalized medicine in 2015 alone.
But far more importantly, PMC augments and
provides a showcase for the ongoing work of its
more than 250 member institutions, which are
advancing the personalized medicine paradigm
despite extraordinary obstacles.
IMPACT
The Coalition’s impact was evidenced by these opening remarks from the
Honorable Fred Upton at a Subcommittee on Health hearing last year, in which the
Congressman cited content from the Coalition’s website:
“According to the Personalized Medicine Coalition, ‘While the potential benefits of
personalized [medicine] are straightforward — knowing what works, knowing why it works,
knowing whom it works for and applying that knowledge to address patient needs — the
intervening variables that determine the pace of personalized medicine’s development
and adoption are far more complex. Among those variables are the laws and regulations
that govern personalized medicine products and services used in clinical practice.’ ”
22. 22
Measuring Progress
PMC Analyses Demonstrate Targeted
Therapies Are Finding Favor at FDA
Eager to showcase its commitment to the field,
FDA requested that PMC conduct an analysis
in January of 2015 to highlight the percentage
of the agency’s 2014 approvals that are
personalized medicines. The results of this
effort were extraordinary.
PMC’s analysis revealed that nine of FDA’s
novel new drug approvals in 2014 are person-
alized medicines, which represents 20 percent
IMPACT I PMC 2015 ANNUAL REPORT
of the total. The analysis supports former FDA
Commissioner Margaret Hamburg’s claim,
issued when she resigned, that FDA had
“ushered in the era of personalized medicine”
under her direction.
PMC followed its examination of 2014 drug
approvals with another analysis in July, recog-
nizing FDA’s record-breaking month for
personalized medicine approvals, during which
it approved four indications for personalized
medicines.
“Ethically and scientifically, there is no going
back,” PMC proclaimed.
Indications Include:
1. Lynparza (olaparib)
2. Vimizim (elosulfase alfa)
3. Cyramza (ramucirumab)
of FDA’s 2014 Novel New Drug Approvals
Were Personalized Medicines
4. Zykadia (ceritinib)
5. Beleodaq (belinostat)
6. Cerdelga (eliglustat)
7. Harvoni (ledipasvir and
sofosbuvir)
8. Viekira Pak (ombitasvir,
paritaprevir and ritonavir;
dasabuvir)
9. Blincyto (blinatumomab)
20%
23. 23
TOWARD
A NEW ERA
As demonstrated by this report and by
PMC’s activities, a new landscape for
personalized medicine is emerging. With
continued support for the education
and advocacy efforts underpinning this
progress, so too will a new era in health
care. Reaching this goal, however, will
require the combined resources of
multiple stakeholders, including govern-
ment — all willing to invest in innovation,
improved outcomes and the reduction of
systemic health care costs.
24. 24
STAFF
Edward Abrahams, Ph.D.
President
202-589-1770
eabrahams@PersonalizedMedicineCoalition.org
Amy M. Miller, Ph.D.
Executive Vice President
202-589-1769
amiller@PersonalizedMedicineCoalition.org
Daryl Pritchard, Ph.D.
Vice President, Science Policy
202-787-5912
dpritchard@PersonalizedMedicineCoalition.org
Mary Bordoni
Director, Membership Development
202-589-0070
mbordoni@PersonalizedMedicineCoalition.org
Faswilla Sampson
Director, Operations Secretary to the Board
202-787-5908
fsampson@PersonalizedMedicineCoalition.org
Christopher J. Wells
Director, Communications
202-589-1755
cwells@PersonalizedMedicineCoalition.org
David L. Davenport
Office Administrator
202-589-1770
ddavenport@PersonalizedMedicineCoalition.org
STAFF I PMC 2015 ANNUAL REPORT
25. 25
BOARD OF DIRECTORS
William S. Dalton, Ph.D., M.D.
Board Chair
M2Gen
Stephen L. Eck, M.D., Ph.D.
Board Vice Chair
Astellas Pharma Global Development
D. Stafford O’Kelly
Board Treasurer
Altan Pharma Ltd.
Amy P. Abernethy, M.D., Ph.D.
Board Secretary
Flatiron Health
Steven D. Averbuch, M.D.
Bristol-Myers Squibb Company
Paul R. Billings, M.D., Ph.D.
Johnson Johnson.
Neil de Crescenzo
Emdeon Inc.
Donna Cryer, J.D.
Global Liver Institute
David Flockhart, M.D., Ph.D.
Indiana Institute for Personalized Medicine
Tim Garnett, F.R.C.O.G., M.F.F.P., F.F.P.M.
Eli Lilly and Company
Julie K. Goonewardene
University of Texas System
Michael Kolodziej, M.D.
Aetna
Howard L. McLeod, Pharm.D.
Moffitt Cancer Center
J. Brian Munroe
Endo Pharmaceuticals
Michael Pellini, M.D.
Foundation Medicine
Kimberly Popovits
Genomic Health
Lori M. Reilly, Esq.
PhRMA
Hakan Sakul, Ph.D.
Pfizer Inc.
Jared N. Schwartz, M.D., Ph.D.
Jared N. Schwartz, M.D., Ph.D., LLC
Michael J. Vasconcelles, M.D.
Unum Therapeutics
Jay G. Wohlgemuth, M.D.
HealthTap
PMC 2015 ANNUAL REPORT I BOARD OF DIRECTORS
26. 26
Indi — Integrated Diagnostics
Interleukin Genetics, Inc.
Leica Biosystems
Luminex Corporation
Metamark Genetics, Inc.
MolecularMD
NanoString Technologies
Novodiax
OncoPlex Diagnostics
Personal Genome Diagnostics (PGDx)
Provista Diagnostics
QIAGEN, Inc.
RIKEN GENESIS
Seegene Technologies, Inc.
Siemens Healthcare Diagnostics, Inc.
SomaLogic, Inc.
Strand Genomics, Inc.
SurExam
Vermillion
EMERGING BIOTECH/
PHARMACEUTICAL COMPANIES
Genomind, LLC
KineMed, Inc.
Metagenics
Onyx Pharmaceuticals
Syros Pharmaceuticals
Zinfandel Pharmaceuticals, Inc.
HEALTH INSURANCE COMPANIES
Aetna
INDUSTRY/TRADE ASSOCIATIONS
American Clinical Laboratory Association
BIO (Biotechnology Industry Organization)
PhRMA
MEMBERSHIP
CLINICAL LABORATORY TESTING SERVICES
AlphaGenomix Laboratories
Clinical Reference Laboratory, Inc.
Laboratory Corporation of America
(LabCorp)
Metabolon, Inc.
Millennium Health
PCLS
Proove Biosciences
Quest Diagnostics
DIAGNOSTIC COMPANIES
Abbott
Adaptive Biotechnologies
Agendia NV
Alacris Theranostics GmbH
Almac Diagnostics
AltheaDX
Assurex Health, Inc.
ASURAGEN, Inc.
BD (Becton Dickinson Company)
Biodesix
Brain Resource Company Limited
Caprion Proteomics
CareDx, Inc.
Caris Life Sciences
Counsyl
Epic Sciences, Inc.
Exact Sciences Corporation
Exosome Diagnostics
Expression Analysis, Inc.
Foundation Medicine, Inc.
GeneCentric Diagnostics
Genomic Health, Inc.
Helomics
Human Longevity
MEMBERSHIP I PMC 2015 ANNUAL REPORT
27. 27
IT/INFORMATICS COMPANIES
5AM Solutions, Inc.
athenahealth
Cytolon AG
DNAnexus
Emdeon
GenoSpace
HealthTap
Inspire
Intel Corporation
M2Gen
McKesson
NextGxDx
Oracle Health Sciences
Syapse
UNIConnect, LC
XIFIN, Inc.
LARGE BIOTECH/
PHARMACEUTICAL COMPANIES
AbbVie
Amgen, Inc.
Astellas Pharma Global Development
AstraZeneca Pharmaceuticals
Boehringer-Ingelheim
Pharmaceuticals, Inc.
Bristol-Myers Squibb
Eli Lilly and Company
EMD Serono
Endo Health Solutions
GE Healthcare
Genentech, Inc.
GlaxoSmithKline, PLC
Johnson Johnson
Takeda Pharmaceuticals International
Company
Teva
Novartis
Pfizer, Inc.
PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple
Sclerosis
Alliance for Aging Research
Bonnie J. Addario Lung Cancer Foundation
Bulgarian Association for Personalized
Medicine
Cancer Commons
Carcinoid — NeuroEndocrine Tumour
Society — Canada
Friends of Cancer Research
Global Liver Institute
HealthyWomen
International Cancer Advocacy Network
(“ICAN”)
LUNGevity Foundation
Melanoma Research Alliance Foundation
Multiple Myeloma Research Foundation
National Alliance for Hispanic Health
National Brain Tumor Society
National Patient Advocate Foundation
One Disease at a Time
Sarcoma Foundation of America
PERSONALIZED MEDICINE SERVICE
PROVIDERS
23andMe
Advanced Individualized Medicine
Cure Forward
InformedDNA
Intervention Insights
KEW Group
Michael J. Bauer, M.D. Associates, Inc.
MolecularHealth
MolecularMatch
NantOmics
N-of-One, Inc.
Perthera
Pharma Research International, Inc.
Precision for Medicine
Tabula Rasa HealthCare, Inc.
PMC 2015 ANNUAL REPORT I MEMBERSHIP
28. 28
RESEARCH, EDUCATION CLINICAL CARE
INSTITUTIONS
American Association for Cancer Research
(AACR)
American Medical Association (AMA)
Association for Molecular Pathology (AMP)
Baylor Health Care System Precision
Medicine Institute
Brown University
Cancer Treatment Centers of America
Catholic Health Initiative’s Center for
Translational Research
The Charles Bronfman Institute for
Personalized Medicine at Mount Sinai
The Christ Hospital
College of American Pathologists
Columbia University — Irving Institute for
Clinical and Translational Research
Coriell Institute for Medical Research
CREATE Health Translational Cancer
Centre, Lund University
Duke University
Essentia Institute of Rural Health
FasterCures
Genome British Columbia
Genome Canada
Génome Québec
Helmholtz Zentrum München
Hospital Universitari Vall d’Hebron
Indiana Institute of Personalized Medicine
Inova Health System
Institute for Systems Biology
Institute for Translational Oncology
Research (ITOR)
Instituto de Salud Carlos III
Intermountain Healthcare
International Society of Personalized
Medicine
The Jackson Laboratory
Knight Cancer Institute — Oregon Health
Sciences University
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson — Institute for Personalized
Cancer Therapy
Mission Health, Fullerton Genetics Center
Moffitt Cancer Center
National Foundation for Cancer Research
National Pharmaceutical Council
NorthShore University HealthSystem
Ontario Genomics Institute
Partners HealthCare Personalized Medicine
Penn State College of Medicine
Poliambulatorio Euganea Medica
Qatar Biobank
The Quebec Network for Personalized
Health Care
Raabe College of Pharmacy,
Ohio Northern University
Roswell Park Cancer Institute
Rutgers Cancer Institute of New Jersey
Sanford Imagenetics, Sanford Health
Stanford University School of Medicine
Sutter Health
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of Florida
University of Pennsylvania Health System
University of Pittsburgh Medical Center
(UPMC)
University of Rochester
University of South Florida Morsani
College of Medicine
The University of Texas System
University of Utah
Vanderbilt University Medical Center
Virginia Commonwealth
University Health System
MEMBERSHIP I PMC 2015 ANNUAL REPORT
29. 29
RESEARCH TOOL COMPANIES
Cynvenio Biosystems, Inc.
DNA Genotek, Inc.
Genia Technologies
Illumina, Inc.
Thermo Fisher Scientific
STRATEGIC PARTNERS
Arnold Porter LLP
Arrowhead Publishers Conferences
Avalere Health
Beaufort, LLC
Big Science Media
Bionest Partners
Bioscience Valuation BSV GmbH
CAHG
Cambridge Healthtech Institute
CKSA
Co-Bio Consulting, LLC
ConText
ConvergeHEALTH by Deloitte
Credit Suisse
Defined Health
Dohmen Life Sciences Services
Dx Economix, Inc.
EdgeTech Law LLP
Ernst Young Global Life Sciences Center
Feinstein Kean Healthcare
Foley Hoag LLP
Foley Lardner LLP
GfK
Goldbug Strategies, LLC
Hanson Wade
HealthFutures, LLC
Hogan Lovells LLP
Jared Schwartz MD, PhD, LLC
The Journal of Precision Medicine
Kinapse
L.E.K. Consulting
Manning Napier Advisors, LLC
McDermott Will Emery
Nixon Peabody LLP
Pendergast Consulting
Personalized Medicine in OncologyTM
Personalized Medicine Partners, LLC
Personalized Medicine World Conference
PricewaterhouseCoopers LLP
Professional Genetic Interactions
Quorum Consulting
Russell Reynolds Associates
Slone Partners
Spectrum
Vital Transformation
VENTURE CAPITAL
GreyBird Ventures, LLC
Kleiner Perkins Caufield Byers
Mohr Davidow Ventures
Third Rock Ventures, LLC
PMC 2015 ANNUAL REPORT I MEMBERSHIP
30. FINANCIAL OVERVIEW
PMC coupled additional revenues from members and sponsors with an effective financial management
strategy to grow its program portfolio in 2014, and has developed an expanded list of potential
sponsorship opportunities to support continued progress in coming years. The Coalition’s staff
is directly responsible for implementing PMC’s programs, with 72 percent of its total expenses
supporting the Coalition’s programming. Revenues were increased by 10 percent in 2014, and PMC
finished the year with seven months’ of expenditures in reserve. The ratio of current assets ($1.5
million) to current liabilities ($368 K) is 4.21 to 1, up from 3.72 to 1 last year.
The financial results are derived from PMC’s IRS form 990 and audited December 31, 2014 finan-
cial statements, which contain an unqualified audit opinion. These documents can be obtained at
pmc@personalizedmedicinecoalition.org or by calling 202.589.1770.
72%
of the Coalition’s expenses support
its programming.
31. 31
2014 2013
Assets
Cash and cash equivalents $ 488,097 $ 528,710
Investments 970,536 505,148
Certificates of deposit - 431,401
Accounts receivable 72,377 55,721
Prepaid expenses and other assets 5,330 10,878
Property and equipment, net 44,107 50,156
Deposits 8,252 8,252
Total assets $1,598,699 $1,590,266
Liabilities and Net Assets
Liabilities
Accounts payable $ 68,046 $ 43,285
Accrued expenses 36,475 3,703
Deferred membership dues 232,975 266,050
Deferred rent payable 25,145 26,127
Deferred sponsorship 5,000 -
Total liabilities 367,641 339,165
Net Assets
Unrestricted 1,231,058 1,251,101
Total net assets 1,231,058 1,251,101
Total liabilities and net assets $1,598,699 $1,590,266
Statements of Financial Position, December 31, 2014 and 2013
32. 32
Unrestricted
Temporarily
Restricted Total
Operating Revenue and Support
Membership dues $1,500,050 $ - $1,500,050
Sponsorship 421,000 - 421,000
Support for PMC Policy - 57,166 57,166
Admission fees—non-members 8,994 - 8,994
Released from restrictions 57,166 (57,166) -
Total operating revenue and support 1,987,210 - 1,987,210
Expenses
Program services:
Education:
State of Personalized Medicine Luncheon 19,119 - 19,119
Membership events 59,193 - 59,193
PMC/BI0 Solutions Summit 4,216 - 4,216
Oncology conference 10,000 - 10,000
Business development: -
Membership development 64,216 - 64,216
Sponsorship/membership 21,800 - 21,800
Stationery and printing 27,964 - 27,964
Total program services 206,508 - 206,508
Supporting services:
General and administrative 1,292,946 - 1,292,946
Professional fees:
Accounting 67,567 - 67,567
Communications 186,435 - 186,435
Consulting fees 204,195 - 204,195
IT support 49,582 - 49,582
Legal - - -
Total supporting services 1,800,725 - 1,800,725
Total expenses 2,007,233 - 2,007,233
Statement of Activities For the Year Ended December 31, 2014
FINANCIAL OVERVIEW I PMC 2015 ANNUAL REPORT
33. 33
2014
Revenues
Unrestricted
Temporarily
Restricted Total
Change in Net Assets from Operations $ (20,023) $ - $ (20,023)
Non-Operating Activities
Interest and dividends 13,715 - 13,715
Unrealized and realized loss on investments (5,612) - (5,612)
Miscellaneous income 4,955 - 4,955
Depreciation (13,078) - (13,078)
Total non-operating activities (20) - (20)
Change in Net Assets (20,043) - (20,043)
Net Assets, beginning of year 1,251,101 - 1,251,101
Net Assets, end of year $1,231,058 - $1,231,058
PMC 2015 ANNUAL REPORT I FINANCIAL OVERVIEW
Membership 75.49%
Sponsorship 21.18%
Other 3.33%
34. 34
“Personalized medicine is our chance
to revolutionize health care, but it will
require a team effort by innovators,
entrepreneurs, regulators, payers and
policymakers.”
— Brook Byers, Partner, Kleiner Perkins Caufield Byers
36. 36
1710 Rhode Island Ave., NW · Suite 700 · Washington, DC 20036
202.589.1770 · pmc@personalizedmedicinecoalition.org
MISSION
STATEMENT
The Personalized Medicine Coalition, representing innovators,
scientists, patients, providers and payers, promotes the
understanding and adoption of personalized medicine concepts,
services and products to benefit patients and the health system.